116 results about "Treatment dose" patented technology

The invention discloses a close-range radiotherapy plan optimization method and device based on a cumulative dose target. The method comprises the following steps: S1, importing current treatment data; s2, leading in a preorder treatment image and performing deformation registration to the current image; s3, mapping the preorder treatment dose to the current treatment image to serve as the background dose of the current treatment; s4, converting the dose data mapped to the current treatment image by the preorder treatment into a bioequivalent dose; s5, on the basis of the sketching data of the current treatment image and with reference to the clinical endangered organ dose limit value requirement, key area generation is carried out on each endangered organ; s6, based on the preorder treatment dosage, generating a corresponding organ-endangered high-risk dosage area and a target area insufficient area according to each organ-endangered dosage limit value and the target area prescription dosage; and S7, optimizing the treatment plan, and optimizing the treatment plan by taking the preorder treated dose and the sum of the planned dose to be optimized at the time to meet the clinical requirement as a target.

Methods, devices, and systems for treating a region of interest (ROI) of skin of a subject or patient in need thereof are disclosed. Such a method of treating a ROI, in some embodiments, comprises irradiating a test region (TR) of the skin with a sub-therapeutic dose of electromagnetic radiation or with a series of sub -therapeutic doses, determining a tissue response of the TR, and generating one or more therapeutic dose parameters based at least in part on the tissue response of the TR. In some embodiments, the method further comprises irradiating the ROI with one or more therapeutic doses of electromagnetic radiation in accordance with the one or more therapeutic dose parameters.

Electrically neutral complex compounds of formula I including any stereoisomer or E / Z isomer thereof wherein: M is Fe < 2 + >, Ru < 2 + >, Os < 2 + >, Co < 3 + >, Rh < 2 + >, Rh < 3 + >, Ir < 3 + >, Ni < 2 + >, Pd < 2 + >, Pt < 2 + > or Pt < 4 + >, in particular Ru < 2 + >; t and T'are H or (C1-C3)-alkyl; lig is a bidentate ligand, in particular 2, 2 '-dipyridyl (bpy) or 4, 7-diphenyl-1, 10-phenanthroline (BPhen); and A is an anion from a pharmaceutically acceptable acid, the electrically neutral complex compounds of formula I are useful in human therapy, in particular as photosensitizers (PS) in photodynamic therapy (PDT) of cancer, skin diseases, fungal infections or microbial infections. They are almost non-toxic under dark conditions at therapeutic doses and exhibit good to excellent photoactivity under hypoxic conditions. They can be used for PDT treatment of deep hypoxia tumors by using light within a far-infrared to near-infrared light treatment window.

The inhalation suspension preparation containing the SGC receptor stimulant comprises the SGC receptor stimulant with an effective therapeutic dose or pharmaceutically acceptable salt of the SGC receptor stimulant, and pharmaceutically acceptable auxiliary materials of the suspension preparation, the pharmaceutically acceptable auxiliary materials of the suspension preparation comprise at least one of a surfactant, a pH regulator, an osmotic pressure regulator and a metal complexing agent; the inhalation suspension preparation containing the riociguat shows good lung absorption efficiency, is beneficial to reaching the same or better treatment level by reducing the administration dosage, can directly act on a diseased region through an administration route, takes effect more quickly compared with oral administration of the riociguat, and has a good application prospect. Gastrointestinal discomfort and systemic hypotension side effects caused by gastrointestinal tract contact and absorption entering a circulatory system can be avoided, the treatment cycle of an oral dosage form dosage titration administration scheme is shortened, and a better treatment scheme is provided for relieving dyspnea and syncope symptoms of pulmonary hypertension patients treated at home.

Techniques for adjusting radiotherapy treatment for a patient in real-time are provided. The techniques include obtaining a training patient anatomy at a first time within a training radiotherapy treatment fraction after a training radiotherapy treatment dose has been delivered by a radiotherapy device; computing a deviation between the training patient anatomy at the first time and reference training patient anatomy during the training radiotherapy treatment fraction, wherein the reference training patient anatomy indicates a prescribed training dose parameter to be delivered within the training radiotherapy treatment fraction; applying the computed deviation to a machine learning model to estimate one or more intra-fraction radiotherapy treatment parameters of a function that provides a radiotherapy device parameter adjustment based on the one or more intra-fraction radiotherapy treatment parameters; and training the machine learning model to establish a relationship between the computed deviation and the one or more intra-fraction radiotherapy treatment parameters.

Disclosed herein are immediate release oral dosage forms that contain abuse-deterrent and abuse-resistant features. In particular, the disclosed dosage forms can provide deterrence of abuse by ingestion of multiple individual doses. The disclosed dosage forms can likewise provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. The dosage forms may also exhibit abuse resistant properties when physically manipulated, and also when physically manipulated and then administered in a manner not consistent with oral dosing. The dosage forms may also exhibit abuse resistant properties when administered in a manner intended to result in administration of the esketamine in a higher than therapeutic dose.

The present application relates to the field of intelligent medical treatment, in particular to a tumor treatment dosing regimen Pareto optimization method based on forward-backward stochastic differential equation. The present application unifies the terminal tumor load, dosing cost and treatment risk into the same stochastic control framework, can establish the Pareto optimality condition corresponding to the nonlinear model, and further converts into the implementable closed-loop state feedback control law in the LQ case. Through the combination with the numerical example and the Pareto frontier analysis, an implementable, interpretable and scalable technical path is provided for the multi-objective individualized treatment regimen design, which can solve the problem that the existing technology is difficult to uniformly process the terminal therapeutic effect, dosing consumption and cumulative risk, and difficult to obtain the implementable closed-loop feedback strategy under the forward-backward stochastic control framework.

The invention provides a BNCT treatment dose accelerated calculation method, a terminal and a treatment planning system. The method comprises the steps of equally dividing each voxel block into a first voxel block and a second voxel block based on a three-dimensional coordinate of each voxel block in a voxel model; alternately iteratively executing the parallel computing process of the first voxel block and the parallel computing process of the second voxel block on the basis of a pre-constructed computing dependency relationship, and obtaining the neutron ejection flow and the neutron flux of each voxel block until an iteration stop condition is met; wherein the dependency calculation relation includes that parallel calculation of the first voxel block depends on neutron outgoing flow of the second voxel block, and parallel calculation of the second voxel block depends on neutron outgoing flow of the first voxel block; and calculating the BNCT therapeutic dose based on the neutron flux of each voxel block. According to the method, on the premise of strictly guaranteeing the calculation precision, a large-scale parallel calculation task set can be formed, the iteration convergence period and the overall calculation time consumption are reduced to the maximum extent, and the requirement for clinically and rapidly calculating the BNCT treatment dose is met.

The present invention concerns dosimetry-related uses and methods that rely on a metastable technetium-99 (99mTc) radionuclide-comprising (dosimetric) radioimmunoconjugate (RIC) to evaluate or establish therapeutic doses of yttrium-90 (90Y) radionuclide-comprising (therapeutic) radioimmunoconjugates, both RICs targeting the same molecular target. More specifically, radioimmunoconjugates that comprise a CD66-binding component are used. Another aspect of the invention relates to Single Time Point dosimetry procedures replacing the need for traditionally used Multiple Time Point dosimetry procedures for yttrium-90 (90Y) radionuclide-comprising radioimmunoconjugates.

The endovenous treatment assembly comprises a wire element (1) for delivering treatment doses, such as for example an optical fiber, which is flexible and capable of being inserted, over part of its length, longitudinally into a vein (V), and a positioning and guiding part (2A), which is integral with the wire element (1) for delivering treatment doses so as to allow manipulation of the wire element (1) for delivering treatment doses by means of this part (2A), the wire element (1) for delivering treatment doses being able to slide in the direction of its length relative to said part (2A);the part (2A) comprises first means for guiding in translation a first portion (110a) of the wire element (1) for delivering treatment doses in the direction of its length and first mechanical assembly means (202, 203) allowing its removable mounting relative to a drive system (4), such that said first portion (110a) of the wire element (1) for delivering treatment doses can be positioned and guided by means of this part (2A) relative to the drive means of the drive system (4) for driving the wire element (1) for delivering treatment doses in the direction of its length at least in a first direction (R).;

The present invention provides a device, system, and method of using the same that can safely and effectively transmit therapeutic or germicidal ultraviolet (UV) radiation, such as UVC radiation or UVA radiation. [Solution] The treatment device comprises a base component and a head component. The head component has a distal portion and a proximal portion. The distal portion of the head component is configured to contact the target eyelid, and the proximal portion is configured to be attached to the base component. The distal portion of the head component is configured to transmit a therapeutic dose of energy from a plurality of energy sources, including an ultraviolet C (UVC) radiation source, an infrared (IR) radiation source, and an ultrasonic source. The plurality of energy sources are configured to transmit a therapeutic dose of energy to the target eyelid at a predetermined output when the distal portion of the head component contacts the eyelid.

Hydration of a larynx and / or vicinity with a composition comprising a salt formulation (e.g., CaCl2, MgCl2, KCl and / or NaCl) can achieve prophylactic and / or therapeutic effects (e.g., cough suppression, improving voice quality, increasing pulse oxygen saturation and / or increasing mucosal vaccination effectiveness). The composition is administered as dry particles (e.g., aerosol) or as a liquid (e.g., solution, aerosol). The liquid can have a pH of 7.0 up to around 10.0, or preferably around 7.5 up to around 9.5, or more preferably around 8.0 up to around 9.0, or even more preferably 8.0 to 8.5 or most preferably around 8.0. The droplets can have a mass median aerodynamic diameter from approximately 8 μm to approximately 15 μm or from approximately 15 μm to approximately 500 μm. A therapeutic dose (e.g., 0.5 mg to 4.0 mg mass of salt) is administered in response to an indication. Such can employ an osmolitically active composition.

The invention discloses an image segmentation method for evaluating a non-small cell lung cancer neutron treatment dose, and relates to the technical field of neutron therapy, and the method comprises the steps: carrying out the training of a 3D U-Net network model through a medical image data set, updating the network parameters and hyper-parameters in the 3D U-Net network model, so as to obtain a trained 3DU-Net network model, and carrying out the evaluation of the neutron treatment dose of the non-small cell lung cancer. In the aspect of processing three-dimensional volume data in an image, information of a space direction can be better reserved, segmentation of a three-dimensional structure can be more accurately carried out, and the segmentation form can accurately reflect an anatomical structure of a patient, a distribution condition of 10B in a body and a radionuclide dynamics condition. Therefore, the information in the medical image can be accurately and fully displayed, and application is facilitated.

The invention belongs to the technical field of biological medicine, and particularly relates to a heparin small molecule antagonist-quaternary ammonium salt macrocyclic compound and a preparation method thereof. The quaternary ammonium salt macrocyclic compound disclosed by the invention comprises three piperazine functionalized quaternary ammonium salt macrorings and four methylated quaternary ammonium salt macrorings; the quaternary ammonium salt macrocyclic compound can be used for preparing a heparin small molecule antagonist. The compound shows excellent antagonism efficiency on ungraded heparin and low-molecular-weight heparin, and shows a wide therapeutic dose window; and the antagonism efficiency and dosage window of the protamine are superior to those of clinically used protamine. Besides, in-vivo and in-vitro safety evaluation proves that the quaternary ammonium salt macrocycle has good biocompatibility, and shows clinical transformation potential as a protamine substitute as a small molecule antagonist.

The instant application describes improved methods and compositions for the systemic delivery of therapeutic exosomes to a subject in need thereof. In certain embodiments, the current invention reduces the amount of exosomes delivered to liver, spleen and combinations thereof to allow greater distribution to other areas of the body such as, but not limited to, the brain, pancreas, lung, kidney, muscle. In certain embodiments, the methods involve the injection of one or multiple doses of non-therapeutic exosomes prior to the injection of a suitable therapeutic dose of exosomes with a therapeutic payload. Also included are methods to improve immune clearance of exosomes in subjects by inhibiting phagocytosis.

The utility model discloses a cell therapy drug delivery device stable in drug delivery, which relates to the technical field of drug delivery devices and comprises a drug storage tube with a drug storage space and a drug delivery head detachably connected to the front end of the drug storage tube; the piston rod is of a hollow structure and can slide in the axial direction of the medicine storage pipe, and the end, extending into the medicine storage pipe, of the piston rod is connected with a piston head. The threaded rod is rotationally arranged in the piston rod, and the outer wall of the threaded rod is in threaded connection with a threaded sleeve capable of sliding in the axial direction of the piston rod; the movable plate is connected to the interior of the medicine storage pipe in a sliding mode, a plurality of through holes are formed in the movable plate, and the front end of the threaded sleeve penetrates through the piston head and is fixedly connected with the center of the movable plate. According to the utility model, the medicine can be stirred and disturbed before being used, so that the uniform distribution of cell exosomes in a target area in the treatment process is ensured, the adverse reaction or invalid treatment condition caused by over-high or over-low local concentration is avoided, and the stability and the accuracy of therapeutic administration are remarkably improved.

It is disclosed herein that that certain alkylphosphocholine analogs are preferentially taken up by malignant pediatric tumor cells. The alkylphosphocholine analogs are compounds having the formula:or salts thereof, wherein n is an integer from 12 to 24; and R2 is —N+(CH3)3. The compounds can be used to treat pediatric solid tumors or to detect pediatric solid tumors. In therapeutic treatment, R1 includes a radioactive iodine isotope that locally delivers therapeutic dosages of radiation to the malignant pediatric tumor cells that preferentially take up the compound. In detection / imaging applications, R1 includes a detection moiety, such as a fluorophore or a radioactive iodine isotope.

The invention provides a method of assessing the appropriate therapeutic dose of 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid to administer to a patient in need thereof, comprising the steps of:(i) testing whether or not the patient has the poor metabolizer genotype; and(ii) if the patient does not have the poor metaboliser genotype, administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at the standard therapeutic dose; and(iii) if the patient does have the poor metaboliser genotype, either(a) administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at a therapeutic dose below that of the standard therapeutic dose; or(b) not administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient.

To provide techniques for predicting the risk of a subject experiencing a cytokine release syndrome of at least a threshold grade subsequent to receiving a treatment.SOLUTION: A risk may be predicted based on, for example, a set of baseline characteristics, a risk-score generation model, an on-treatment cytokine level, and / or a treatment dosage. The risk may be used to generate an output corresponding to a recommendation as to whether to monitor the subject via in-patient monitoring.SELECTED DRAWING: Figure 1

A method is provided to modulated vascular adaptation within a tumor so that therapy uptake is increased. The method includes providing a pressure directed therapy system having an infusion lumen, an occluder, a pressure sensor to sense pressure distal of the occluder. The distal end of the system is advanced to a target artery of an organ. The pressure in the target artery is reduced by expanding the occluder at the distal end of the system. Then, the therapy is infused through the infusion lumen and into the target artery. Upon sensing decreased pressure and thus vessel adaptation, infusion is stopped until vessel re-adaptation occurs. Then infusion resumes. The infusion continues in a cycle of therapy infusing, sensing pressure and determining vessel adaptation, waiting, and resuming once re-adaptation occurs until the therapy dose is delivered to the patient.

Systems and methods are disclosed for treating back pain associated with a vertebral body of a patient. The system may include an external energy source configured to be positioned at a location external to the body of the patient, a linear configured to drive translation of the external source in one or more axes, a computer coupled to the external source and linear drive and programming executable on said computer for determining a target treatment site within or near the vertebral body based on acquired imaging data, positioning a focal point of the external energy source to substantially coincide with the target treatment site, and delivering a treatment dose of therapeutic energy at said target treatment site, wherein the treatment dose is configured to modulate a nerve within or near the vertebral body.

Systems, devices, and techniques are disclosed for differentiating a therapeutic dose and a priming event to properly administer medication to patients. In one example aspect, a method for differentiating therapeutic doses and priming events in administering a medication to a patient includes determining a time window for monitoring dispensing of the medication by an injection pen device. Multiple dispense events each releasing an amount of the medication occur in the time window. The method also includes classifying dispense events prior to a last dispense event in the time window as priming events or therapeutic doses and designating the last dispense event in the time window as a therapeutic dose for facilitating calculation and tracking of a dosage amount for the patient.

The invention relates to the technical field of intelligent medical control and low-temperature plasma medical application, in particular to an intelligent decision-making system for CAP treatment of nephropathy skin complications based on multi-parameter dynamic monitoring. Comprising a multi-modal physical sign acquisition module which is used for acquiring multi-dimensional physiological characterization signals of local tissues and synchronously acquiring periodic metabolism interference data containing dialysis time sequence information; the tolerance threshold inversion module is used for obtaining a local tissue oxidation-reduction tolerance threshold through inversion by using a tissue oxidation-reduction tolerance calculation model; the dynamic interference compensation module is used for generating a real-time safety boundary threshold value; the adaptive strategy generation module is used for generating candidate treatment control strategies by using a deep reinforcement learning algorithm; the risk boundary control module is used for calculating an expected oxidative stress level, if the expected oxidative stress level is larger than or equal to a real-time safety boundary threshold value, blocking or degrading operation is executed, and otherwise, a final treatment instruction is output; the therapeutic dose control precision is improved to the physiological response level, and the iatrogenic skin necrosis risk is effectively avoided.

This invention relates to the use of inhibitors of IL-6 or IL-6R for treating graft-versus-host disease (GVHD) in a subject, including acute GVHD (aGVHD) or chronic GVHD (cGVHD). In particular, this invention relates to methods of treatment of GVHD in a subject in need thereof, wherein the treatment is a first-line treatment of GVHD, the method comprising a combination therapy of (i) administration to the subject of an antibody or fragment which is capable of inhibiting human IL-6 or human IL-6 receptor; and (ii) administration to the subject of a corticosteroid; wherein the administration of the antibody or fragment is given in a first treatment dose within the period 24 hours before or after initiation of the administration of the corticosteroid.

The application discloses application of a compound SCH23390 in preparation of a medicine for treating lead poisoning, and relates to the technical field of medicines. The application studies the efficiency of the compound SCH23390 in treatment of lead poisoning, first discloses the treatment effect of the compound SCH23390 on lead poisoning, breaks through the limitation of an existing drug target point, directly corrects abnormal nerve signals by inhibiting excessive activation of D1 neurons, avoids side effects of central excessive excitation, and has no significant toxic side effects under a treatment dose. In particular, the compound SCH23390 can significantly relieve specific abnormal behavior phenotypes caused by low-dose lead poisoning, and exhibits better neuroprotective characteristics than traditional chelating agents. The application breaks through the limitation of a single chelating antidote in the traditional field of lead poisoning treatment, and provides a new direction for development of anti-lead toxicity medicines with multiple target points and multiple mechanisms.

Methods are provided for treating a subject with cancer, with a therapeutic dose of annexin V to the subject.

The utility model relates to the technical field of ultrasonic treatment equipment, in particular to an automatic treatment device with image guidance, which is characterized in that a host is arranged on one side of a control console, a follow-up arm is mounted on the control console, a first mounting hole is formed in the working end of the follow-up arm, a colposcope is mounted in the first mounting hole, a treatment arm is mounted at the working end of the follow-up arm, and the treatment arm is mounted on the control console. A second mounting hole and a third mounting hole are formed in the treatment arm, a treatment gun is mounted in the second mounting hole, a laser head is mounted in the third mounting hole, and the laser head, the treatment gun and the colposcope are all connected with the console. A colposcope image corresponds to coordinate information positioned by a laser head, so that accurate positioning and uniform movement of a treatment position are realized, non-uniform speed and inaccurate position of a treatment gun which is manually moved are avoided, and the treatment efficiency is improved; visualization of a real-time path and an ultrasonic dose when the treatment gun works is achieved, the condition of the treatment process is known in real time, the ultrasonic treatment dose is accurately mastered, the treatment position is accurately positioned, and the treatment mode is optimized.

To provide use of an anti-CD38 antibody as an agent for treating cancers such as multiple myeloma or in the manufacture of such an agent.SOLUTION: The present invention relates to an antibody that specifically binds CD38 and is capable of killing a CD38+ cell by induction of apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity. The antibody of the present disclosure may be used as a preparation or in the manufacture of a preparation, wherein the antibody is to be administered to a human subject in a safe therapeutic dose of about 20 mg / kg or below. In one embodiment, the preparation is for treating CD38+ multiple myeloma in humans.SELECTED DRAWING: None

A method and compositions of matter for treating or preventing an auto-immune disorder or immune response in a patient, that includes providing a therapeutic dose to the patient of a substituted indole compound having at least one substitution, wherein the substituted indole compound has only one thiol group, and wherein the ring the thiol group is attached to only contains one N or O atom.

Systems and methods are disclosed for treating back pain associated with a vertebral body of a patient. The system may include an external energy source configured to be positioned at a location external to the body of the patient, a linear configured to drive translation of the external source in one or more axes, a computer coupled to the external source and linear drive and programming executable on said computer for determining a target treatment site within or near the vertebral body based on acquired imaging data, positioning a focal point of the external energy source to substantially coincide with the target treatment site, and delivering a treatment dose of therapeutic energy at said target treatment site, wherein the treatment dose is configured to modulate a nerve within or near the vertebral body.